BNF:

4.7.2

Status:

Grey, Green

Decision Date:

October 2022

Comments

GREEN: Twice daily MR preparations. MR preparations to be prescribed by brand (Zomorph most cost effective).

GREY: Once daily MR preparation - MXL. Reserved for use when twice daily MR preparations are not appropriate. (Decision date - March 2018)  

GREY: Morphine orodispersible - For exceptional use where risk assessment indicates. (Decision date - August/October 2022)

• risk of harm to self or through confusion
• chronic pain and at risk of intentional overdose (e.g. depression, EUPD)
• pain/palliative care and at risk of unintentional overdose (dementia, Alzheimer’s)
• additional patient factors e.g. poor manual dexterity

Grey Drug Classifications

• 4: Lack of data on cost-effectiveness compared with standard therapy
• 5: Less cost-effective than current standard therapy

search again